You searched for "malware"

528 results found

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Paediatric ptosis

Manoj Parulekar and colleagues provide a comprehensive overview of the diagnosis, assessment and management of childhood ptosis. Blepharoptosis (commonly referred to as ptosis – Greek, πτῶσις, ‘to fall’) is a condition where the upper eyelid is in an abnormally low...

My Top Five: Emerging technologies revolutionising ophthalmology

Advancements in ophthalmology have significantly transformed eyecare practices. This article explores five emerging technologies that are revolutionising the field, from virtual reality (VR) surgical training to novel therapies for corneal conditions. These innovations are reshaping how eyecare professionals diagnose, treat...

Should we move towards procedure-specific consent forms?

The consent process represents the patient’s acceptance of the information provided to them and an agreement to undergo an intervention as suggested by a health professional. Effective doctor-patient communication, ensuring the succinct delivery of the necessary points in a way...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease

Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...

Viva Las Vegas: Dr Corey Hochman

Speaking with Phoenix-based ophthalmologist and poker player, Dr Corey Hochman, Peter Cackett explores the themes of success and failure, and how the ups and downs of one’s ambition can provide an overwhelming gratitude for life. “Money won is twice as...

“I can see fine. Why do I need my eyes tested?”

Are routine eye examinations really necessary? The author asks whether frequent appointments in low-risk patients with normal results are actually cost-effective. It’s recommended that most people should get their eyes tested every two years.” [1] This message is widely publicised...

Biometry and IOL choice errors

In the next instalment of this series I focus on problems associated with biometry and intraocular lens (IOL) selection for cataract surgery. I have taken previous medicolegal cases I have dealt with and tried to extract some learning points and...

The most frequent complaints and claims in ophthalmology – a Medical Protection Society (MPS) analysis

The authors look at the reasons behind medico-legal cases reported to MPS and share key learning points. Complications following ophthalmology surgery are rare, however, medico-legal cases are not uncommon due to the significant impact they can have on patients’ lifestyles....

Cataract surgery training in the independent sector

I am now most of the way through my ST3 year working in Plymouth, within the Peninsula Deanery. Before the start of the year, I was approached by one of my consultants who asked if I would like to carry...

How to write and publish a case report – tips and common pitfalls

Ophthalmology is an extremely popular specialty, with the competition ratio at ST1 level entry being 10:1 in 2023 [1]. Consequently, applicants are required to achieve higher portfolio scores to remain competitive. For those considering a career in ophthalmology, two points...